AU5508798A - Diagnostic and therapeutic reagents for alzheimer's disease - Google Patents

Diagnostic and therapeutic reagents for alzheimer's disease

Info

Publication number
AU5508798A
AU5508798A AU55087/98A AU5508798A AU5508798A AU 5508798 A AU5508798 A AU 5508798A AU 55087/98 A AU55087/98 A AU 55087/98A AU 5508798 A AU5508798 A AU 5508798A AU 5508798 A AU5508798 A AU 5508798A
Authority
AU
Australia
Prior art keywords
alzheimer
diagnostic
disease
therapeutic reagents
reagents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55087/98A
Inventor
Ralf Hoffmann
Virginia M-Y. Lee
Laszlo Otvos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Wistar Institute of Anatomy and Biology
Original Assignee
University of Pennsylvania Penn
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, Wistar Institute of Anatomy and Biology filed Critical University of Pennsylvania Penn
Publication of AU5508798A publication Critical patent/AU5508798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU55087/98A 1996-11-19 1997-11-19 Diagnostic and therapeutic reagents for alzheimer's disease Abandoned AU5508798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3116996P 1996-11-19 1996-11-19
US60031169 1996-11-19
PCT/US1997/021116 WO1998022120A1 (en) 1996-11-19 1997-11-19 Diagnostic and therapeutic reagents for alzheimer's disease

Publications (1)

Publication Number Publication Date
AU5508798A true AU5508798A (en) 1998-06-10

Family

ID=21857983

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55087/98A Abandoned AU5508798A (en) 1996-11-19 1997-11-19 Diagnostic and therapeutic reagents for alzheimer's disease

Country Status (2)

Country Link
AU (1) AU5508798A (en)
WO (1) WO1998022120A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0866805A1 (en) 1995-12-12 1998-09-30 Karolinska Innovations AB PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
EP1301531A2 (en) * 2000-07-11 2003-04-16 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
AR052051A1 (en) 2004-12-15 2007-02-28 Neuralab Ltd AB HUMANIZED ANTIBODIES USED TO IMPROVE COGNITION
RU2442793C2 (en) 2005-11-30 2012-02-20 Эбботт Лэборетриз ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES
KR101906161B1 (en) 2005-11-30 2018-10-11 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (en) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MX2011009654A (en) * 2009-03-18 2011-10-12 Ac Immune Sa Method for therapeutic use.
UA107571C2 (en) * 2009-04-03 2015-01-26 PHARMACEUTICAL COMPOSITION
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2440234A4 (en) * 2009-06-10 2013-11-06 Univ New York Immunological targeting of pathological tau proteins
IN2012DN00446A (en) * 2009-07-30 2015-05-15 Pfizer Vaccines Llc
ES2684475T3 (en) 2010-04-15 2018-10-03 Abbvie Inc. Proteins that bind to beta amyloid
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
EP2987807A3 (en) * 2010-10-07 2016-06-01 AC Immune S.A. Antibodies recognising phospho-tau
LT2627672T (en) * 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Human anti-tau antibodies
JP6358953B2 (en) * 2011-10-07 2018-07-18 エーシー イミューン エス．エー． Phospho-specific antibody that recognizes tau
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
US9834596B2 (en) 2012-07-03 2017-12-05 Washington University Antibodies to tau
WO2014016737A1 (en) * 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
BR112015003326A2 (en) 2012-08-16 2017-07-04 Ipierian Inc methods of treatment of a tauopathy
AU2013361107B2 (en) 2012-12-21 2018-08-23 Biogen International Neuroscience Gmbh Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
MX2015012872A (en) 2013-03-15 2016-02-03 Ac Immune Sa Anti-tau antibodies and methods of use.
PT3083680T (en) 2013-12-20 2020-03-17 Hoffmann La Roche Humanized anti-tau(ps422) antibodies and methods of use
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
AR100978A1 (en) 2014-06-26 2016-11-16 Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
TW202136296A (en) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 Humanized anti-tau antibodies
CN107073297B (en) 2014-07-08 2021-09-14 纽约大学 Tau imaging ligands and their use in diagnosis and treatment of tauopathies
ES2809728T3 (en) 2015-06-24 2021-03-05 Hoffmann La Roche Humanized anti-tau (pS422) antibodies and procedures for use
CN108135986B (en) 2015-08-13 2022-07-29 纽约大学 Antibody-based molecules specific for a truncated Asp421 epitope of Tau and their use in the diagnosis and treatment of Tau disease
AR113792A1 (en) 2017-10-25 2020-06-10 Janssen Pharmaceuticals Inc COMPOSITIONS OF PHOSPHORILED TAU PEPTIDES AND THEIR USES
AU2019244481A1 (en) * 2018-03-28 2020-10-01 Axon Neuroscience Se Antibody-based methods of detecting and treating Alzheimer's disease
AU2020219804A1 (en) 2019-02-08 2021-08-19 Ac Immune S.A. Method of safe administration of phosphorylated Tau peptide vaccine
EA202192891A1 (en) 2019-04-24 2022-02-04 Янссен Фармасьютикалз, Инк. HETEROLOGICAL ADMINISTRATION OF ANTI-TAU VACCINES
BR112021021062A2 (en) * 2019-05-31 2021-12-14 Lilly Co Eli Compounds and methods that target human tau

Also Published As

Publication number Publication date
WO1998022120A1 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
AU5508798A (en) Diagnostic and therapeutic reagents for alzheimer's disease
AU1407399A (en) Treatment for alzheimer's disease
AU3891499A (en) Diagnostic tests for alzheimer's disease
AU2414092A (en) Diagnostic method for alzheimer's disease
AU3590897A (en) Traveler's quarters
IL105216A0 (en) Method and kit for the diagnosis of alzheimer's disease
AU7556994A (en) Methods for the diagnosis of alzheimer's disease
IL119417A0 (en) Drug for Parkinson's disease
ZA989365B (en) Preparation for treating alzheimer's disease
HUP0003684A3 (en) Diagnostic test for alzheimer's disease
AU4636993A (en) Diagnosing alzheimer's disease and schizophrenia
AU5153398A (en) Diagnostic method for the detection of alzheimer's disease in living patients
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
AU1405899A (en) Treatment for alzheimer's disease
AU3068899A (en) Diagnostic assay for late-onset alzheimer's disease
AU9017098A (en) Method for diagnosing alzheimer's disease
AU6401696A (en) Early onset alzheimer's disease gene and gene products
AU7847198A (en) Therapeutic antioxidants for alzheimer's disease
AU5495398A (en) Idebenone containing combination agent for treating alzheimer's disease
AU3500497A (en) Hodgkin's disease associated molecules and uses thereof
AU1072195A (en) Diagnosis of alzheimer's disease
AU5157493A (en) Protein specific for alzheimer's disease and method of diagnosing alzheimer's disease through detection of the protein
AU718732C (en) Diagnostic assay for Alzheimer's disease
GB9517266D0 (en) Diagnosis of alzheimer's disease
GB9418854D0 (en) Diagnosis of alzheimer's disease